-
Atomoxetine, sold
under the
brand name Strattera, is a
medication used to
treat attention deficit hyperactivity disorder (ADHD) and, to a
lesser extent...
- (Edronax),
developed as a first-line
therapy for
major depressive disorder.
Atomoxetine (Strattera) is
another potent and
selective NRI
which is also effective...
- Non-stimulant
medications with a
specific indication for ADHD
include atomoxetine (Strattera),
viloxazine (Qelbree),
guanfacine (Intuniv), and clonidine...
- non-stimulant medications,
atomoxetine and viloxazine, are
approved by the FDA and in
other countries for the
treatment of ADHD.
Atomoxetine, due to its lack of...
-
produces moderate reductions in symptoms; it is
about as
effective as
atomoxetine and
methylphenidate but with
fewer side effects.
Viloxazine was previously...
- the following:
Selective norepinephrine reuptake inhibitors Marketed Atomoxetine (Strattera)
Reboxetine (Edronax, Vestra)
Viloxazine (Qelbree, Vivalan)...
- Vivalan) – also a 5-HT2B
receptor antagonist and 5-HT2C
receptor agonist Atomoxetine (Strattera)
Bupropion (Wellbutrin, Elontril) – also a non-competitive...
-
because of the high
dosage required and
potential for
severe side effects.
Atomoxetine (or
reboxetine in Europe) is an
adrenergic reuptake inhibitor which increases...
-
trial found that the
combination of
piracetam and
atomoxetine was more
effective than
atomoxetine alone.
While piracetam may be an
effective adjuvant...
- 2-4 hours. For ADHD, the
effectiveness of
methylphenidate is
comparable to
atomoxetine but
modestly lower than amphetamines.
Common adverse reactions of methylphenidate...
